What the women in the trials reported
PT-141 is another name for bremelanotide. The two trials reported together studied women who hadn't reached menopause and had hypoactive sexual desire disorder. That means low sexual desire that causes distress; we'll leave the long name there.
The trials compared bremelanotide with a placebo, a dummy treatment, for 24 weeks. Chance determined which treatment each woman received. Researchers measured changes in desire and in the distress linked to low desire.
Women receiving bremelanotide improved more on those measures than women receiving placebo. That's evidence of an effect in the groups studied. It doesn't tell us how much any one woman's everyday experience changed.
We find the two parts of the question useful. Desire is one thing; how someone feels about low desire is another. Keeping both in view gives us a clearer account than a sweeping claim about better sex.
Nausea, flushing and headache were common side effects. The prescribing information also warns about a temporary rise in blood pressure. It rules out use in people with uncontrolled high blood pressure or known heart and blood-vessel disease.
The approved medicine is a prescription injection of bremelanotide. The label specifies acquired and generalized HSDD and limits the use to women before menopause. Acquired means this wasn't always a problem; generalized means it occurs across situations, rather than with just one partner. PT-141 research chemicals are outside that approval. It also excludes use in men, after menopause or for general sexual enhancement.
For someone wondering whether the result relates to their own life, a licensed U.S. clinician can assess the problem and discuss approved treatment where appropriate. The paper gives us something specific to talk about. It can't diagnose the reader.
That is where the question passes from a paper to an individual assessment. At Promise Peptides (mypromise.com), a licensed clinician reviews a woman's health before prescribing compounded PT-141, which is not FDA-approved; care is limited to U.S. patients; some patients are declined.
We'd keep the result in those everyday words: desire improved and related distress eased more than with placebo. That's worth understanding on its own. It doesn't need to become a promise about the rest of someone's intimate life.